Cortex Pharm Inc (CORX) 0.0190 $CORX
Fragile X Syndrome Pipeline Review 2015 - 10 Companies & 20 Company Profiles
M2 - Fri Jul 10, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js4sb7/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - Confluence Pharmaceuticals LLC - Cortex Pharmaceuticals, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Selvita SA Drug Profiles - acamprosate calcium - basimglurant - Bryostatin-1 - cercosporamide - CX-929 - Drugs to Inhibit mGluR5 for Fragile X Syndrome - flindokalner - gaboxadol - ganaxolone - Metadoxine ER - minocycline - NNZ-2591 - SEL-203 - Small Molecule for FXTAS - Small Molecule to Activate Epsilon PKC for Fragile X Syndrome - Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Small Molecules to Agonize 5-HT7 for Fragile X Syndrome - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278 - trofinetide For more information visit http://www.researchandmarkets.com/research/js4sb7/fragile_x
MRNS: 13.62 (+1.72), ADHD: 6.46 (+0.33), LLY: 88.29 (+0.81)
Cortex Pharmaceuticals, Inc. Announces Partnership With the Knowledge Translation Strategy Unit of the Canadian Institutes of Health Research on the Use of Ampakines in the Alleviation of Respiratory Depression
Marketwired - Tue Jun 30, 8:02AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"
is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. The Company owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their use in the treatment of various disorders. These patents cover, among other compounds, the Company's lead ampakines CX1739 and CX1942 and extend through at least 2028.
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 141.67 (+1.54), SRPT: 30.02 (+0.66), FOLD: 14.48 (+0.44)
Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders
GlobeNewswire - Mon May 04, 8:03AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" announces the recent publication of two key scientific papers co-authored by the Chairman of the Company's Scientific Advisory Board, Dr. John Greer, Ph.D. that show the positive effects of the Company's ampakines CX1739 and CX717 in treating respiratory distress in a perinatal premature rat pup model and a genetic mouse model of Pompe Disease. Cortex is a leader in developing drugs for respiratory disorders, particularly sleep apnea (both obstructive and central) and drug-induced respiratory depression.
Cortex Pharmaceuticals, Inc. to Present at NewYorkBIO 25th Anniversary Conference
GlobeNewswire - Fri May 01, 8:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at the NewYorkBIO 25 Anniversary Conference (http://conference.newyorkbio.org). The conference will take place on May 4 - 5, 2015 at 10 on the Park @ Time Warner Center.
Global Respiratory Depression Pipeline Review 2015 - 2 Companies & 8 Drug Profiles
M2 - Mon Apr 27, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59hbpn/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals Drug Profiles - CX-1739 - CX-1942 - CX-2007 - CX-2076 - doxapram hydrochloride - GAL-021 - GAL-021 Successors - tianeptine For more information visit http://www.researchandmarkets.com/research/59...espiratory
Cortex Pharmaceuticals, Inc. Files December 31, 2014 Annual Report on Form 10-K; Provides Update on Current Status and Activities
GlobeNewswire - Mon Apr 06, 5:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression.
Sleep Apnea Therapeutics Pipeline Review 2015 - 4 Companies & 11 Drug Profiles
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pw3nkj/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals - Rottapharm SpA - SK Biopharmaceuticals Co., Ltd. Drug Profiles - CX-1739 - CX-2007 - CX-2076 - dexloxiglumide - doxapram hydrochloride - dronabinol - GAL-021 - GAL-160 - GAL-160 Backups - itriglumide - SKL-N05 For more information visit http://www.researchandmarkets.com/research/pw...leep_apnea
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Report: 2015 Edition
M2 - Wed Feb 18, 6:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/26hd3f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace. Revised and updated 11th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2009 to end of December 2014. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking Chapter 3 - Overview of co-promotion deal structure Chapter 4 - Overview of co-marketing deal structure Chapter 5 - Leading co-promotion deals Chapter 6 - Leading co-marketing deals Chapter 7 - Big pharma co-promotion and co-marketing deals Chapter 8 - Co-promotion agreement contracts directory 2009-2014 Chapter 9 - Co-marketing agreement contracts directory 2009-2014 Companies Mentioned - Abbott - Allergan - Alnylam Pharmaceuticals - Ambit Biosciences - Amgen - Clarient - Columbia Laboratories - Cortex Pharmaceuticals - Eli Lilly - Embryome Sciences - Enanta Pharmaceuticals - Ironwood Pharmaceuticals - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe - NovaBay Pharmaceuticals - Novartis - Novo Nordisk - Procter & Gamble - Roche - Sagent Pharmaceuticals - Sanofi - Synta Pharmaceuticals - Takeda - Takeda Pharmaceutical - Targacept - Teva - Xenoport - Zogenix - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/26...motion_and
AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), CBRX: 7.36 (+0.45), ENTA: 45.53 (+1.12), AGN: 312.13 (+8.03), JNJ: 99.53 (+1.13), SNTA: 2.16 (-0.01), NVO: 57.68 (+2.91), IRWD: 11.44 (-0.06), MRK: 57.95 (+0.57), SGNT: 25.90 (+0.16), PG: 80.95 (+0.29), NVS: 103.22 (+3.20)
Cortex Pharmaceuticals, Inc. to Present at 7th Annual Biotech Showcase(TM) 2015
GlobeNewswire - Fri Jan 09, 7:07AM CST
Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at Biotech Showcase(TM) 2015 (www.ebdgroup.com/bts/index.php). The conference is co-sponsored by the EBD Group and Demy-Colton Life Sciences Advisors and will be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, California from January 12 - 15, 2015.
Fragile X Syndrome Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014
PRWeb - Sun Dec 07, 1:31PM CST
The report "Fragile X Syndrome Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Fragile X Syndrome is the most common inherited form of mental problems and this disease caused by changes in a single X. Complete Report is Available @ http://www.rnrmarketresearch.com/fragile-x-sy...eport.html .
MRNS: 13.62 (+1.72), PRTK: 26.83 (+0.73)
Cortex Pharmaceuticals, Inc. to Participate in 7th Annual Biotech Showcase 2015(TM) Being Held in San Francisco, California From January 12 - 15, 2015
GlobeNewswire - Tue Dec 02, 7:00AM CST
Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly drug-induced respiratory depression as well as obstructive, central and mixed sleep apneas, announces that it will be participating in and presenting at the 7 Annual Biotech Showcase 2015(TM) being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 - 15, 2015. The Company will be providing additional information with respect to its presentation at this event in early 2015.
Cortex Pharmaceuticals, Inc. Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression, as well as obstructive, central and mixed sleep apnea, announces that effective September 18, 2014, the Company has entered into an agreement with the National Institute of Drug Abuse valued at $148,583 and entitled "Novel Treatment of Drug-Induced Respiratory Depression." The funding is a Phase 1 award granted under the Small Business Innovation Research Funding Award Program. The purpose of this project is to determine the most useful injectable route of administration for CX1942, the Company's proprietary, soluble ampakine, a potential rescue medication for drug-induced respiratory depression and lethality. Under the terms of the funded program, preclinical studies will be performed in collaboration with Dr. David Fuller, of the University of Florida, and Dr. John Greer, of the University of Alberta.
Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:00PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, particularly drug-induced respiratory depression as well as obstructive, central and mixed sleep apneas, announces that it will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference (www.rodm.com). The conference will be held September 8 - 10, 2014 at the New York Palace Hotel sponsored by H.C. Wainwright & Co., LLC. The Company's Executive Chairman and CEO, Arnold S. Lippa, Ph.D., is currently scheduled to present at 3:45pm EDT on Wednesday, September 10, 2014.
Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors.
CTRV: 5.60 (+0.15), BMY: 69.27 (+1.38), TBRA: 17.24 (+0.72)
Fragile X Syndrome Pipeline Review 2015 - 10 Companies & 20 Company Profiles
M2 - Fri Jul 10, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js4sb7/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aelis Farma S.A.S. - Alcobra Ltd - Confluence Pharmaceuticals LLC - Cortex Pharmaceuticals, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Marinus Pharmaceuticals, Inc. - MI.TO. Technology S.r.L. - Neuren Pharmaceuticals Limited - Selvita SA Drug Profiles - acamprosate calcium - basimglurant - Bryostatin-1 - cercosporamide - CX-929 - Drugs to Inhibit mGluR5 for Fragile X Syndrome - flindokalner - gaboxadol - ganaxolone - Metadoxine ER - minocycline - NNZ-2591 - SEL-203 - Small Molecule for FXTAS - Small Molecule to Activate Epsilon PKC for Fragile X Syndrome - Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Small Molecules to Agonize 5-HT7 for Fragile X Syndrome - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - SRT-278 - trofinetide For more information visit http://www.researchandmarkets.com/research/js4sb7/fragile_x
MRNS: 13.62 (+1.72), ADHD: 6.46 (+0.33), LLY: 88.29 (+0.81)
Cortex Pharmaceuticals, Inc. Announces Partnership With the Knowledge Translation Strategy Unit of the Canadian Institutes of Health Research on the Use of Ampakines in the Alleviation of Respiratory Depression
Marketwired - Tue Jun 30, 8:02AM CDT
Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"
is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. The Company owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their use in the treatment of various disorders. These patents cover, among other compounds, the Company's lead ampakines CX1739 and CX1942 and extend through at least 2028. Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 141.67 (+1.54), SRPT: 30.02 (+0.66), FOLD: 14.48 (+0.44)
Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders
GlobeNewswire - Mon May 04, 8:03AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
announces the recent publication of two key scientific papers co-authored by the Chairman of the Company's Scientific Advisory Board, Dr. John Greer, Ph.D. that show the positive effects of the Company's ampakines CX1739 and CX717 in treating respiratory distress in a perinatal premature rat pup model and a genetic mouse model of Pompe Disease. Cortex is a leader in developing drugs for respiratory disorders, particularly sleep apnea (both obstructive and central) and drug-induced respiratory depression. Cortex Pharmaceuticals, Inc. to Present at NewYorkBIO 25th Anniversary Conference
GlobeNewswire - Fri May 01, 8:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at the NewYorkBIO 25 Anniversary Conference (http://conference.newyorkbio.org). The conference will take place on May 4 - 5, 2015 at 10 on the Park @ Time Warner Center. Global Respiratory Depression Pipeline Review 2015 - 2 Companies & 8 Drug Profiles
M2 - Mon Apr 27, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59hbpn/respiratory) has announced the addition of the "Respiratory Depression - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals Drug Profiles - CX-1739 - CX-1942 - CX-2007 - CX-2076 - doxapram hydrochloride - GAL-021 - GAL-021 Successors - tianeptine For more information visit http://www.researchandmarkets.com/research/59...espiratory
Cortex Pharmaceuticals, Inc. Files December 31, 2014 Annual Report on Form 10-K; Provides Update on Current Status and Activities
GlobeNewswire - Mon Apr 06, 5:00AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. Sleep Apnea Therapeutics Pipeline Review 2015 - 4 Companies & 11 Drug Profiles
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pw3nkj/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cortex Pharmaceuticals, Inc. - Galleon Pharmaceuticals - Rottapharm SpA - SK Biopharmaceuticals Co., Ltd. Drug Profiles - CX-1739 - CX-2007 - CX-2076 - dexloxiglumide - doxapram hydrochloride - dronabinol - GAL-021 - GAL-160 - GAL-160 Backups - itriglumide - SKL-N05 For more information visit http://www.researchandmarkets.com/research/pw...leep_apnea
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Report: 2015 Edition
M2 - Wed Feb 18, 6:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/26hd3f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace. Revised and updated 11th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2009 to end of December 2014. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in co-promotion and co-marketing dealmaking Chapter 3 - Overview of co-promotion deal structure Chapter 4 - Overview of co-marketing deal structure Chapter 5 - Leading co-promotion deals Chapter 6 - Leading co-marketing deals Chapter 7 - Big pharma co-promotion and co-marketing deals Chapter 8 - Co-promotion agreement contracts directory 2009-2014 Chapter 9 - Co-marketing agreement contracts directory 2009-2014 Companies Mentioned - Abbott - Allergan - Alnylam Pharmaceuticals - Ambit Biosciences - Amgen - Clarient - Columbia Laboratories - Cortex Pharmaceuticals - Eli Lilly - Embryome Sciences - Enanta Pharmaceuticals - Ironwood Pharmaceuticals - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe - NovaBay Pharmaceuticals - Novartis - Novo Nordisk - Procter & Gamble - Roche - Sagent Pharmaceuticals - Sanofi - Synta Pharmaceuticals - Takeda - Takeda Pharmaceutical - Targacept - Teva - Xenoport - Zogenix - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/26...motion_and
AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), CBRX: 7.36 (+0.45), ENTA: 45.53 (+1.12), AGN: 312.13 (+8.03), JNJ: 99.53 (+1.13), SNTA: 2.16 (-0.01), NVO: 57.68 (+2.91), IRWD: 11.44 (-0.06), MRK: 57.95 (+0.57), SGNT: 25.90 (+0.16), PG: 80.95 (+0.29), NVS: 103.22 (+3.20)
Cortex Pharmaceuticals, Inc. to Present at 7th Annual Biotech Showcase(TM) 2015
GlobeNewswire - Fri Jan 09, 7:07AM CST
Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression, announces that it will be presenting at Biotech Showcase(TM) 2015 (www.ebdgroup.com/bts/index.php). The conference is co-sponsored by the EBD Group and Demy-Colton Life Sciences Advisors and will be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, California from January 12 - 15, 2015. Fragile X Syndrome Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014
PRWeb - Sun Dec 07, 1:31PM CST
The report "Fragile X Syndrome Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects. Fragile X Syndrome is the most common inherited form of mental problems and this disease caused by changes in a single X. Complete Report is Available @ http://www.rnrmarketresearch.com/fragile-x-sy...eport.html .
MRNS: 13.62 (+1.72), PRTK: 26.83 (+0.73)
Cortex Pharmaceuticals, Inc. to Participate in 7th Annual Biotech Showcase 2015(TM) Being Held in San Francisco, California From January 12 - 15, 2015
GlobeNewswire - Tue Dec 02, 7:00AM CST
Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly drug-induced respiratory depression as well as obstructive, central and mixed sleep apneas, announces that it will be participating in and presenting at the 7 Annual Biotech Showcase 2015(TM) being held at the Parc 55 Wyndham Hotel in San Francisco, California from January 12 - 15, 2015. The Company will be providing additional information with respect to its presentation at this event in early 2015. Cortex Pharmaceuticals, Inc. Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression, as well as obstructive, central and mixed sleep apnea, announces that effective September 18, 2014, the Company has entered into an agreement with the National Institute of Drug Abuse valued at $148,583 and entitled "Novel Treatment of Drug-Induced Respiratory Depression." The funding is a Phase 1 award granted under the Small Business Innovation Research Funding Award Program. The purpose of this project is to determine the most useful injectable route of administration for CX1942, the Company's proprietary, soluble ampakine, a potential rescue medication for drug-induced respiratory depression and lethality. Under the terms of the funded program, preclinical studies will be performed in collaboration with Dr. David Fuller, of the University of Florida, and Dr. John Greer, of the University of Alberta. Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:00PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, particularly drug-induced respiratory depression as well as obstructive, central and mixed sleep apneas, announces that it will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference (www.rodm.com). The conference will be held September 8 - 10, 2014 at the New York Palace Hotel sponsored by H.C. Wainwright & Co., LLC. The Company's Executive Chairman and CEO, Arnold S. Lippa, Ph.D., is currently scheduled to present at 3:45pm EDT on Wednesday, September 10, 2014. Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"
, a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors. CTRV: 5.60 (+0.15), BMY: 69.27 (+1.38), TBRA: 17.24 (+0.72)
